Effects of Raloxifene and GnRH-a on VEGF expression in cultured human uterine leiomyoma cells

Abstract

Background: uterine leiomyoma is the most common benign pelvic tumor in women of reproductive age and is frequently associated with abnormal uterine bleeding and pelvic pressure. Combined therapy of gonadotropin-releasing hormone analogue (GnRH-a) and selective estrogen receptor inhibitors (raloxifene) reduce the size of leiomyoma.